Adalimumab, injection, 40 mg in 0.8 mL, pre-filled syringe, pre-filled pen, Humira® - November 2010
Page last updated: 02 March 2011
PDF printable version for Adalimumab, injection, 40 mg in 0.8 mL, pre-filled syringe,
pre-filled pen, Humira ® (PDF 122 KB)
Product: Adalimumab, injection, 40 mg in 0.8 mL,
pre-filled syringe, pre-filled pen, Humira®
Sponsor: Abbott Australasia Pty Ltd
Date of PBAC Consideration: November 2010
1. Purpose of Application
The submission requested an extension to the current Authority
Required PBS listing for Crohn disease to include patients with
fistulae.
2. Background
Adalimumab had not previously been considered by the PBAC for the
fistulising Crohn disease indication.
Adalimumab is currently listed on the PBS for the treatment of
severe active rheumatoid arthritis, severe active psoriatic
arthritis, active ankylosing spondylitis, severe refractory Crohn
disease, severe chronic plaque psoriasis and juvenile idiopathic
arthritis.
At the March 2010 PBAC meeting, infliximab was recommended for
listing as a pharmaceutical benefit under Section 100 (Highly
Specialised Drugs Program) for treatment of complex refractory
fistulising Crohn disease with a draining enterocutaneous or
rectovaginal fistula, on the basis of a high, but acceptable,
cost-effectiveness ratio, in the context of a serious medical
condition that has a large impact on the quality of life of often
otherwise healthy younger patients.
In terms of assessment for continuing therapy, the PBAC accepted
that response could be assessed as either closure of at least 50%
of the number of externally draining fistulae (i.e. no drainage
despite finger pressure in at least 50% of fistulae) or a marked
reduction in drainage of all fistulae together with less pain and
induration as reported by the patient.
3. Registration Status
Adalimumab was TGA registered on 26 June 2007 for the treatment of
moderate to severe Crohn disease in adults to reduce the signs and
symptoms of the disease and to induce and maintain clinical
remission in patients who have had an inadequate response to
conventional therapies, or who have lost response to or are
intolerant of infliximab.
The PBAC considered fistulising disease to be a manifestation of
moderate to severe Crohn disease, and that it was reasonable to
interpret that the TGA approved indication includes patients with
fistulising disease.
4. Listing Requested and PBAC’s View
The submission requested a restriction similar to that for
infliximab for fistulising Crohn disease.
For PBAC’s view, see Recommendation and
Reasons.
5. Clinical Place for the Proposed Therapy
Adalimumab is proposed as an alternative treatment to infliximab
for fistulising Crohn disease.
6. Comparator
The submission nominated infliximab as the comparator. The PBAC
agreed that this was appropriate.
7. Clinical Trials
The submission presented an indirect comparison of adalimumab and infliximab with
placebo as the common reference using a sub-group of adalimumab treated patients who
had fistulae from the CHARM study (the CHARM sub-group) and infliximab treated patients
from ACCENT II.
In the CHARM study, patients with moderate to severe Crohn disease (CDAI ≥ 220 - ≤
450) were treated with 80 mg adalimumab at week 0, and 40 mg adalimumab at week 2
and subsequently randomised to adalimumab 40 mg every other week or placebo. In ACCENT
II, patients with fistulising Crohn disease were treated with infliximab 5 mg/kg at
weeks 0, 2 and 6 and were subsequently randomised to infliximab (5 mg/kg every 8 weeks)
or placebo maintenance. Publication details of the studies presented in the submission
are in the table below.
Trial ID / First author | Protocol title / Publication title | Publication citation |
Adalimumab (common reference placebo) | ||
CHARM Colombel J-F, et al. Colombel J-F, et al. Feagan BG, et al. |
Adalimumab for the treatment of fistulas in patients with Crohn disease. Adalimumab for maintenance of clinical response and remission in patients with Crohn disease: The CHARM trial. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn disease: results from the CHARM study. |
Gut 2009; 58: 940-948 Gastroenterology 2007; 132: 52-65 Gastroenterology 2008; 135 1493-1499 |
Infliximab (common reference placebo) | ||
ACCENT II Sands BE, et al. Sands BE, et al. Sands BE, et al. Lichtenstein GR, et al. Lichtenstein GR, et al. |
Infliximab maintenance therapy for fistulising Crohn disease. Maintenance infliximab does not result in increased abscess development in fistulising Crohn disease: results from the ACCENT II study. Long-term treatment of rectovaginal fistulas in Crohn disease: response to infliximab in the ACCENT II study. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulising Crohn disease. Clinical trial: Benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomised trials. |
New England Journal of Medicine 2004; 350(9): 876-885 Alimentary Pharmacol & Therapeutics 2006; 23: 1127-1136 Clinical Gastroenterology and Hepatology 2004; 2: 912-920 Gastroenterology 2005; 128: 862-869 Alimentary Pharmacol & Therapeutics 2009; 30: 210-226 |
The PBAC noted that there were different inclusion and exclusion criteria between
the CHARM and ACCENT II trials which suggested that patients treated with adalimumab
had more severe disease. For the CHARM trial, selection was primarily based on a CDAI
score of ≥ 220, ≤ 450 and the presence of fistulae was not an entry criterion. Selection
in ACCENT II was based on the presence of chronic fistulae irrespective of the CDAI.
Under the PBS eligibility criteria for the severe refractory Crohn indication (CDAI
≥ 300), 60% of patients in the CHARM trial and 34% of patients in ACCENT II would
be PBS eligible. The PBAC noted the sponsor’s pre-PBAC response which claimed that
baseline CDAI score is not a significant treatment effect modifier. The PBAC also
noted the lower induction dose of adalimumab used in the CHARM trial (80 mg at week
0, 40 mg at week 2) compared with the TGA-approved doses for adalimumab in Crohn disease
(i.e. 160 mg at week 0 and 80 mg at week 2), and the small number of patients in the
CHARM sub-group (n=30).
8. Results of Trials
The results for the CHARM sub-group were those for whom response
and non-response was demonstrated at week 4 (following the
induction doses) and those for the ACCENT II trial were only those
for patients who achieved a response at both weeks 10 and 14 of the
trial and thus assessed the maintenance of that response. The
submission argued that as the CHARM sub-group included both
responders and non-responders, this would bias against adalimumab,
however the PBAC considered that it was possible that this may
favour adalimumab as the response rates reported at 26 and 56 weeks
may include those patients who had an initial response and
maintained it as well as patients who achieved response after
prolonged exposure to adalimumab.
The table below summarises the comparative effectiveness of
adalimumab and infliximab in terms of complete fistula closure at
week 56.
Proportion of subjects with complete fistula closure at
trial endpoint (week 56)
Adalimumab n/N (%) | Placebo n/N (%) | Infliximab n/N (%) | RD (95%CI) p-value | RR (95%CI) p-value | |
CHARM sub-group | 11/30 (36.7%) | 6/47 (12.8%) | - | 23.9 (4.2, 43.6) p=0.018 | 2.87 (1.19, 6.95) p=0.019 |
ACCENT II | - | 19/98 (19.4%) | 33/91 (36.3%) | 16.9 (4.3, 29.5) p=0.009 | 1.87 (1.15, 3.04) p=0.012 |
Indirect comparison: Indirect RR (95%CI) | 1.54 (0.54, 4.21) | ||||
Indirect comparison: Indirect OR (95%CI) | 1.67 (0.45,6.20) |
Abbreviations: RD: risk difference; RR: relative risk; CI:
confidence interval; OR: odds ratio.
Bold typography indicates statistically significant
differences
The efficacy analyses of complete fistula closure data in the CHARM
sub-group were performed on the intention-to-treat (ITT) sub-group
dataset to analyse drug effect on fistulae in all subjects with
draining cutaneous fistulae, whilst efficacy analyses of fistula
data in ACCENT II were performed on the modified ITT dataset and
did not include non-responders. The submission stated that the
ACCENT II analysis may overestimate the efficacy of infliximab as
it does not include initial non-responders, however this is more
representative of the PBS restriction where only responders at week
12 are eligible to continue treatment. As a result, an indirect
comparison of outcomes from the two trials may be biased in favour
of infliximab. However, as the CHARM sub-group included responders
and non-responders, the PBAC considered that the reported number of
responders at week 56 may be overestimated as these patients may
include some patients who achieved treatment response over time
with prolonged exposure to adalimumab (i.e. >12 weeks), which is
not consistent with the proposed restriction, rather than only
those who achieved response after initial treatment and maintained
that response.
The PBAC noted that the placebo arms of the CHARM sub-group and
ACCENT II were not comparable. In the CHARM sub-group, all patients
received the induction doses (80 mg at week 0 and 40 mg at week 2)
and were subsequently randomised to adalimumab or placebo. This is
in contrast to the proposed initial treatment with adalimumab (160
mg at week 0, 80 mg at week 2 and 40 mg every other week thereafter
for a maximum of 16 weeks) and assessment of response at week 12.
Conversely, all patients in ACCENT II received the induction doses
of infliximab (at weeks 0, 2 and 6, consistent with its PBS
restriction) and were subsequently randomised to infliximab or
placebo maintenance. The PBAC considered that given the placebo arm
of the CHARM sub-group did not receive the full initial treatment,
unlike those in ACCENT II, it is possible that the response rate in
the placebo arm of the CHARM sub-group is underestimated.
The submission presented an analysis to estimate maintenance of
response which compared only patients with an initial response, and
demonstrated the efficacy of the treatments in maintaining that
response.
The results of the indirect comparison suggested that there was no
difference in the proportion of responders with a loss of response
at study endpoint between patients treated with adalimumab and
infliximab. However, it was noted that this analysis was informed
by only a small number of patients and therefore the results were
only indicative.
No new safety concerns for either adalimumab or infliximab were
identified from those already known to be associated with each of
the treatments.
9. Clinical Claim
The submission described adalimumab as non-inferior in terms of
comparative effectiveness and non-inferior in terms of comparative
safety over infliximab.
The PBAC recalled that adalimumab and infliximab have been shown to
be equivalent in other indications and considered that the
submission’s claim of non-inferiority in fistulising Crohn
disease was not unreasonable.
10. Economic Analysis
The submission claimed cost-minimisation for adalimumab with
infliximab, although no cost-minimisation analysis was presented.
The price requested for adalimumab for fistulising Crohn disease
was the same as that for its current listing for severe refractory
Crohn disease. This was accepted by the PBAC. The equi-effective
doses have previously been accepted by the PBAC as adalimumab 160
mg at week 0, 80 mg at week 2 and 40 mg every second week for
maintenance subject to response and infliximab 5 mg/kg at week 0, 2
and 6 and every eight weeks thereafter subject to response for
severe refractory Crohn disease.
11. Estimated PBS Usage and Financial Implications
The submission estimated the likely number of patients per year to
be less than 10,000 in Year 5 for the total population eligible for
both adalimumab and infliximab.
The financial cost per year to the PBS was estimated in the
submission to be in the range of $10 – 15 million in Year 1
for the total market size of adalimumab and infliximab.
These were considered possible underestimates.
12. Recommendation and Reasons
The PBAC recommended the listing of adalimumab on the PBS as an
Authority Required benefit for the treatment of complex, refractory
fistulising Crohn disease with a draining enterocutaneous or
rectovaginal fistula on a cost-minimisation basis with infliximab,
at the same price as the current listing for adalimumab for severe
refractory Crohn disease.
The PBAC noted the TGA approved indication for adalimumab is for
treatment of moderate to severe Crohn disease, without specific
reference to fistulising disease. However, the PBAC considered
fistulising disease to be a manifestation of moderate to severe
Crohn disease, and that it was reasonable to interpret that the TGA
approved indication includes patients with fistulising
disease.
The PBAC considered a restriction consistent with the current
listing for infliximab for fistulising disease, using the same
adalimumab doses used in the listing for severe refractory Crohn
disease was appropriate. The PBAC recommended that patients be
permitted to cycle between PBS-subsidised infliximab and adalimumab
using similar criteria to those for the severe refractory Crohn
disease listings.
The PBAC noted that a proportion of patients with fistulising
disease and a CDAI score ≥ 300 are already able to access
PBS-subsidised adalimumab under the current Crohn disease listing.
However, there may be patients with worse fistulae but with a lower
CDAI who are not currently eligible and that this represents an
equity issue. The PBAC noted that the presence of fistulae adds
only around 20 points to the overall CDAI score. The PBAC also
noted that there was a high clinical need for an alternative
treatment that can be given by an alternative route other than
intravenously and that morbidity of the disease is high.
The PBAC agreed that infliximab was the appropriate
comparator.
The PBAC considered there were a number of areas of uncertainty
with the indirect comparison presented in the submission, which
used a sub-group of adalimumab treated patients with fistulae from
the CHARM trial, and infliximab treated patients from ACCENT-II,
with placebo as the common reference. Specifically, the PBAC noted
the lower induction dose of adalimumab used in the CHARM trial (80
mg at week 0, 40 mg at week 2) compared with the TGA approved doses
for Crohn disease (160 mg at week 0, 80 mg at week 2). There were
also differences in the inclusion and exclusion criteria between
the trials which suggest that patients treated with adalimumab had
more severe disease. The PBAC noted the sponsor’s pre-PBAC
response which claimed that baseline CDAI score is not a
significant treatment effect modifier. The PBAC also noted the
small number of patients in the CHARM sub-group (n=30).
The PBAC noted that the results of the indirect comparison
suggested that patients treated with adalimumab are more likely to
have complete fistula closure compared with patients treated with
infliximab (RR=1.54, [95% CI 0.54, 4.21]). The difference was not
statistically significant, however, the trials were not
specifically powered to detect differences in this outcome. The
PBAC considered that, as adalimumab and infliximab have been shown
to be equivalent in other indications and have been cost-minimised
in Crohn disease, a cost-minimisation recommendation was acceptable
on the basis of the data presented and high clinical need.
The PBAC noted the consumer comments for this item.
Recommendation:
ADALIMUMAB, injection, 40 mg in 0.8 mL, pre-filled syringe,
pre-filled pen
Extend the current restriction to include:
NOTE:
Any queries concerning the arrangements to prescribe adalimumab may
be directed to Medicare Australia on 1800 700 270 (hours of
operation 8 a.m. to 5 p.m. EST Monday to Friday).
Prescribing information (including Authority Application Forms) is
available on the Medicare Australia website at
www.medicareaustralia.gov.au.
Written applications for authority to prescribe adalimumab should
be forwarded to:
Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001
NOTE;
TREATMENT OF COMPLEX REFRACTORY FISTULISING CROHN DISEASE
The following information applies to the prescribing under the
Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab
for patients with complex refractory fistulising Crohn disease.
Where the term 'tumour necrosis factor (TNF) alfa antagonist'
appears in the following NOTES and restrictions, it refers to
adalimumab and infliximab only.
A patient is eligible for PBS-subsidised treatment with only 1 of
the 2 TNF-alfa antagonists at any 1 time.
From [start date], under the PBS, all patients will be able to
commence a treatment cycle where they may trial each PBS-subsidised
TNF-alfa antagonist without having to experience a disease flare
when swapping to the alternate agent. Under these
interchangeability arrangements, within a single treatment cycle, a
patient may continue to receive long-term treatment with a TNF-alfa
antagonist while they continue to show a response to therapy.
A patient who received PBS-subsidised TNF-alfa antagonist treatment
prior to [start date] is considered to be in their first cycle as
of [start date].
Within the same treatment cycle, a patient cannot trial and fail,
or cease to respond to, the same PBS-subsidised TNF-alfa antagonist
more than twice.
Once a patient has either failed or ceased to respond to treatment
3 times, they are deemed to have completed a treatment cycle and
they must have, at a minimum, a 5-year break in PBS-subsidised
TNF-alfa antagonist therapy before they are eligible to commence
the next cycle. The 5-year break is measured from the date of the
last approval for PBS-subsidised TNF-alfa antagonist treatment in
the most recent cycle to the date of the first application for
initial treatment with a TNF-alfa antagonist under the new
treatment cycle.
A patient who has failed fewer than 3 trials of TNF-alfa
antagonists in a treatment cycle and who has a break in therapy of
less than 5 years, may commence a further course of treatment
within the same treatment cycle.
A patient who has failed fewer than 3 trials of TNF-alfa
antagonists in a treatment cycle and who has a break in therapy of
more than 5 years, may commence a new treatment cycle.
There is no limit to the number of treatment cycles a patient may
undertake in their lifetime.
(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy
after [start date].
(a) Initial treatment.
Applications for initial treatment should be made where:
(i) a patient has received no prior PBS-subsidised TNF-alfa
antagonist treatment in this treatment cycle and wishes to commence
such therapy (Initial 1); or
(ii) a patient has received prior PBS-subsidised (initial or
continuing) TNF-alfa antagonist therapy and wishes to trial an
alternate agent (Initial 2) [further details are under 'Swapping
therapy' below]; or
(iii) a patient wishes to re-commence treatment with a specific
TNF-alfa antagonist following a break in PBS-subsidised therapy
with that agent (Initial 2).
Initial treatment authorisations will be limited to provide for a
maximum of 16 weeks of therapy for adalimumab and 14 weeks of
therapy for infliximab.
From [start date], a patient must be assessed for response to any
course of initial PBS-subsidised treatment following a minimum of
12 weeks of therapy for adalimumab and up to 12 weeks after the
first dose (6 weeks following the third dose) for infliximab, and
this assessment must be submitted to Medicare Australia no later
than 4 weeks from the date that course was ceased.
Where a response assessment is not submitted to Medicare Australia
within these timeframes, the patient will be deemed to have failed
to respond to treatment with that TNF-alfa antagonist.
For second and subsequent courses of PBS-subsidised TNF-alfa
antagonist treatment, it is recommended that a patient is reviewed
in the month prior to completing their current course of treatment
and that an application is posted to Medicare Australia no later
than 2 weeks prior to the patient completing their current
treatment course.
Adalimumab only: Two completed authority prescriptions must be
submitted with every initial application for adalimumab. One
prescription must be for the induction pack containing a quantity
of 6 doses of 40 mg and no repeats. The second prescription must be
written for 2 doses of 40 mg and 2 repeats.
(b) Continuing treatment. Following the completion of an initial
treatment course with a specific TNF-alfa antagonist, a patient may
qualify to receive up to 24 weeks of continuing treatment with that
drug providing they have demonstrated an adequate response to
treatment. The patient remains eligible to receive continuing
TNF-alfa antagonist treatment with the same drug in courses of up
to 24 weeks providing they continue to sustain the response.
It is recommended that a patient be reviewed in the month prior to
completing their current course of treatment to ensure
uninterrupted TNF-alfa antagonist supply.
Assessments of response to a course of PBS-subsidised therapy must
be submitted to Medicare Australia no later than 4 weeks from the
date that course was ceased.
Where a response assessment is not submitted to Medicare Australia
within these timeframes, the patient will be deemed to have failed
to respond to treatment with that TNF-alfa antagonist.
(2) Swapping therapy.
Once initial treatment with the first PBS-subsidised TNF-alfa
antagonist is approved, a patient may swap if eligible to the
alternate TNF-alfa antagonist within the same treatment cycle.
A patient may trial the alternate TNF-alfa antagonist at any
time, regardless of whether they are receiving therapy (initial or
continuing) with a TNF-alfa antagonist at the time of the
application. However, they cannot swap to a particular TNF-alfa
antagonist if they have failed to respond to prior treatment with
that drug two times within the same treatment cycle.
To ensure a patient receives the maximum treatment opportunities
allowed under the interchangeability arrangements, it is important
that they are assessed for response to every course of treatment
approved, within the timeframes specified in the relevant
restriction.
To avoid confusion, an application for a patient who wishes to swap
to the alternate TNF-alfa antagonist should be accompanied by the
approved authority prescription or remaining repeats for the
TNF-alfa antagonist the patient is ceasing.
(3) Baseline measurements to determine response.
Medicare Australia will determine whether a response to treatment
has been demonstrated based on the baseline measurements submitted
with the first authority application for a TNF-alfa antagonist.
However, prescribers may provide new baseline measurements any time
that an initial treatment authority application is submitted within
a treatment cycle and Medicare Australia will assess response
according to these revised baseline measurements.
(4) Re-commencement of treatment after a 5-year break in
PBS-subsidised therapy.
A patient who wishes to trial a second or subsequent treatment
cycle following a break in PBS-subsidised TNF-alfa antagonist
therapy of at least 5 years, must requalify for initial treatment
with respect to the indices of disease severity.
(5) Patients 'grandfathered' onto PBS-subsidised treatment with
adalimumab or infliximab.
A patient who commenced treatment with adalimumab for complex
refractory fistulising Crohn disease prior to 4 November 2010 or
infliximab prior to 1 March 2010 and who continues to receive
treatment at the time of application, may qualify for treatment
under the initial 'grandfather' treatment restriction.
A patient may only qualify for PBS-subsidised treatment under this
criterion once. A maximum of 24 weeks of treatment with adalimumab
or infliximab will be authorised under this criterion.
Following completion of the initial PBS-subsidised course, further
applications for treatment with adalimumab or infliximab will be
assessed under the continuing treatment restriction.
'Grandfather' arrangements will only apply for the first treatment
cycle. For the second and subsequent cycles, a 'grandfather'
patient must requalify for initial treatment under the criteria
that apply to a new patient. See 'Re-commencement of treatment
after a 5-year break in PBS-subsidised therapy' above for further
details.
No applications for increased maximum quantities and/or repeats will be authorised.
Authority Required
Initial 1
Initial treatment of complex refractory FISTULISING CROHN
DISEASE.
Initial PBS-subsidised treatment with adalimumab by a
gastroenterologist or a consultant physician as specified in the
NOTE below, of a patient with complex refractory fistulising Crohn
disease who:
(a) has confirmed Crohn disease, defined by standard clinical,
endoscopic and/or imaging features, including histological
evidence, with the diagnosis confirmed by a gastroenterologist or a
consultant physician as specified in the NOTE below; and
(b) has an externally draining enterocutaneous or rectovaginal
fistula; and
(c) has signed a patient acknowledgement indicating they understand
and acknowledge that PBS-subsidised treatment will cease if they do
not meet the predetermined response criteria for ongoing
PBS-subsidised treatment, as outlined in the restriction for
continuing treatment.
NOTE: Prescribers must be gastroenterologists (code 87), consultant
physicians [internal medicine specialising in gastroenterology
(code 81)] or consultant physicians [general medicine specialising
in gastroenterology (code 82)].
Authority applications must be made in writing and must
include:
(a) two completed authority prescription forms; and
(b) a completed Fistulising Crohn Disease PBS Authority Application
- Supporting Information Form [may be downloaded from the Medicare
Australia website (www.medicareaustralia.gov.au)] which includes
the following:
(i) a completed current Fistula Assessment Form including the date
of assessment of the patient's condition; and
(ii) a signed patient acknowledgement.
The most recent fistula assessment must be no more than 1 month old
at the time of application.
A maximum of 16 weeks treatment will be authorised under this
criterion.
Two completed authority prescriptions must be submitted with every
initial application for adalimumab. One prescription must be for
the induction pack containing a quantity of 6 doses of 40 mg and no
repeats. The second prescription must be written for 2 doses of 40
mg and 2 repeats. Where fewer than 2 repeats are requested at the
time of the application, authority approvals for sufficient repeats
to complete a maximum of 16 weeks of treatment with adalimumab may
be requested by telephone by contacting Medicare Australia on 1800
700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).
Under no circumstances will telephone approvals be granted for
initial authority applications, or for treatment that would
otherwise extend the initial treatment period.
An assessment of the patient's response to this initial course
of treatment must be made following a minimum of 12 weeks of
therapy so that there is adequate time for a response to be
demonstrated.
This assessment must be submitted to Medicare Australia no later
than 1 month from the date of completion of this initial course of
treatment. Where a response assessment is not undertaken and
submitted to Medicare Australia within these timeframes, the
patient will be deemed to have failed to respond to treatment with
adalimumab.
It is recommended that an application for continuing treatment is
posted to Medicare Australia at the time of the 12 week assessment,
to ensure continuity of treatment for those patients who meet the
continuation criterion for PBS-subsidised adalimumab treatment.
Authority Required
Initial 2
Change or re-commencement of treatment of complex refractory
FISTULISING CROHN DISEASE.
Initial PBS-subsidised treatment with adalimumab of complex
refractory fistulising Crohn disease by a gastroenterologist or a
consultant physician as specified in the NOTE below, of a patient
with complex refractory fistulising Crohn disease who:
(a) has a documented history of complex refractory fistulising
Crohn disease; and
(b) in this treatment cycle, has received prior PBS-subsidised
treatment with adalimumab or infliximab for a draining
enterocutaneous or rectovaginal fistula; and
(c) has not failed PBS-subsidised therapy with adalimumab for this
condition more than once in the current treatment cycle.
NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].
To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the time frames specified in the relevant restriction.
Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.
If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.
Authority applications must be made in writing and must
include:
(a) two completed authority prescription forms; and
(b) a completed Fistulising Crohn Disease PBS Authority Application
- Supporting Information Form [may be downloaded from the Medicare
Australia website (www.medicareaustralia.gov.au)] which includes
the following:
(i) a completed current Fistula Assessment Form including the
date of assessment of the patient's condition; and
details of prior TNF-alfa antagonist treatment including details of
date and duration of treatment.
The most recent fistula assessment must be no more than 1 month old
at the time of application.
A maximum of 16 weeks treatment will be authorised under this
criterion.
Two completed authority prescriptions must be submitted with every
initial application for adalimumab. One prescription must be for
the induction pack containing a quantity of 6 doses of 40 mg and no
repeats. The second prescription must be written for 2 doses of 40
mg and 2 repeats. Where fewer than 2 repeats are requested at the
time of the application, authority approvals for sufficient repeats
to complete a maximum of 16 weeks of treatment with adalimumab may
be requested by telephone by contacting Medicare Australia on 1800
700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).
Under no circumstances will telephone approvals be granted for
initial authority applications, or for treatment that would
otherwise extend the initial treatment period.
An assessment of the patient's response to this initial course
of treatment must be made following a minimum of 12 weeks of
therapy so that there is adequate time for a response to be
demonstrated.
This assessment must be submitted to Medicare Australia no later
than 1 month from the date of completion of this initial course of
treatment. Where a response assessment is not undertaken and
submitted to Medicare Australia within these timeframes, the
patient will be deemed to have failed to respond to treatment with
adalimumab.
It is recommended that an application for continuing treatment is
posted to Medicare Australia at the time of the 12 week assessment,
to ensure continuity of treatment for those patients who meet the
continuation criterion for PBS-subsidised adalimumab
treatment.
Authority Required
Initial 3 (grandfather)
Initial PBS-subsidised treatment of complex refractory
FISTULISING CROHN DISEASE in a patient who has previously received
non-PBS-subsidised therapy with adalimumab.
Initial PBS-subsidised supply for continuing treatment with
adalimumab by a gastroenterologist, a consultant physician as
specified in the NOTE below, or other consultant physician in
consultation with a gastroenterologist of a patient who satisfies
the following criteria:
(a) has a documented history of complex refractory fistulising
Crohn disease and was receiving treatment with adalimumab prior to
4 November 2010; and
(b) had a draining enterocutaneous or rectovaginal fistula(e) prior
to commencing treatment with adalimumab; and
(c) has signed a patient acknowledgement indicating that they
understand and acknowledge that PBS-subsidised treatment will cease
if they do not meet the predetermined response criteria for ongoing
PBS-subsidised treatment, as outlined in the restriction for
continuing treatment; and
(d) is receiving treatment with adalimumab at the time of
application; and
(e) has demonstrated or sustained an adequate response to treatment
with adalimumab.
NOTE: Prescribers must be gastroenterologists (code 87), consultant
physicians [internal medicine specialising in gastroenterology
(code 81)] or consultant physicians [general medicine specialising
in gastroenterology (code 82)].
An adequate response to adalimumab treatment is defined as:
(a) a decrease from baseline in the number of open draining
fistulae of greater than or equal to 50%; and/or
(b) a marked reduction in drainage of all fistula(e) from baseline,
together with less pain and induration as reported by the
patient.
Applications for authorisation must be made in writing and must
include:
(a) a completed authority prescription form; and
(b) a completed Fistulising Crohn Disease PBS Authority Application
- Supporting Information Form [may be downloaded from the Medicare
Australia website (www.medicareaustralia.gov.au)] which includes
the following:
(i) a completed current and baseline Fistula Assessment form
including the date of assessment of the patient's condition;
and
(ii) a signed patient acknowledgement.
The current fistula assessment must be no more than 1 month old at
the time of application.
The baseline fistula assessment must be from immediately prior to
commencing treatment with adalimumab.
An assessment of the patient's response to a continuing course of
therapy must be made within the 4 weeks prior to completion of that
course and posted to Medicare Australia no less than 2 weeks prior
to the date the next dose is scheduled, in order to ensure
continuity of treatment for those patients who meet the
continuation criteria.
Where an assessment is not submitted to Medicare Australia within
these timeframes, patients will be deemed to have failed to
respond, or to have failed to sustain a response, to treatment with
adalimumab.
A maximum of 24 weeks treatment will be approved under this
criterion.
Where fewer than 5 repeats are requested at the time of
application, authority approvals for sufficient repeats to complete
a maximum of 24 weeks of treatment may be requested by telephone by
contacting Medicare Australia on 1800 700 270 (hours of operation 8
a.m. to 5 p.m. EST Monday to Friday).
Patients may qualify for PBS-subsidised treatment under this
restriction once only.
Authority Required
Continuing treatment of complex refractory FISTULISING CROHN
DISEASE.
Continuing PBS-subsidised treatment with adalimumab by a
gastroenterologist, a consultant physician as specified in the NOTE
below or other consultant physician in consultation with a
gastroenterologist, of a patient who:
(a) has a documented history of complex refractory fistulising
Crohn disease; and
(b) has demonstrated or sustained an adequate response to treatment
with adalimumab.
NOTE: Prescribers must be gastroenterologists (code 87), consultant
physicians [internal medicine specialising in gastroenterology
(code 81)] or consultant physicians [general medicine specialising
in gastroenterology (code 82)].
An adequate response is defined as:
(a) a decrease from baseline in the number of open draining
fistulae of greater than or equal to 50%; and/or
(b) a marked reduction in drainage of all fistula(e) from baseline,
together with less pain and induration as reported by the
patient.
Authority applications must be made in writing and must
include:
(a) a completed authority prescription form; and
(b) a completed Fistulising Crohn Disease PBS Authority Application
- Supporting Information Form [may be downloaded from the Medicare
Australia website (www.medicareaustralia.gov.au)] which includes a
completed Fistula Assessment form including the date of the
assessment of the patient's condition.
The fistula assessment must be no more than 1 month old at the time
of application.
If the application is the first application for continuing
treatment with adalimumab, an assessment of the patient's response
must be made following a minimum of 12 weeks after the first dose
so that there is adequate time for a response to be
demonstrated.
An assessment of the patient's response to a continuing course of
therapy must be made within the 4 weeks prior to completion of that
course and posted to Medicare Australia no less than 2 weeks prior
to the date the next dose is scheduled, in order to ensure
continuity of treatment for those patients who meet the
continuation criteria.
Where an assessment is not submitted to Medicare Australia within
these timeframes, patients will be deemed to have failed to
respond, or to have failed to sustain a response, to treatment with
adalimumab.
Patients are eligible to receive continuing adalimumab treatment in
courses of up to 24 weeks providing they continue to sustain the
response.
A maximum of 24 weeks treatment will be authorised under this
criterion.
Where fewer than 5 repeats are requested at the time of
application, authority approvals for sufficient repeats to complete
a maximum of 24 weeks of treatment may be requested by telephone by
contacting Medicare Australia on 1800 700 270 (hours of operation 8
a.m. to 5 p.m. EST Monday to Friday).
Maximum quantity: 1 (x6) Initial 1 and 2
2 (x1) All indications
Repeats: 0 (x6) Initial 1 and 2
2 (x1) Initial 1 and 2
5 (x1) Initial 3 and Continuing
13. Context for Decision
The PBAC helps decide whether and, if so, how medicines should be
subsidised in Australia. It considers submissions in this context.
A PBAC decision not to recommend listing or not to recommend
changing a listing does not represent a final PBAC view about the
merits of the medicine. A company can resubmit to the PBAC or seek
independent review of the PBAC decision.
14. Sponsor’s Comment
The Sponsor is pleased that patients will have a treatment alternative that can be administered subcutaneously for fistulising Crohn disease.